姚劲波“跨界”卖药：豪掷6亿，易明医药营收两连跌

Core Viewpoint - The entry of Yao Jinbo, founder of 58.com, into the pharmaceutical industry through the acquisition of controlling interest in Yiming Pharmaceutical marks a significant shift for both the company and the industry, with performance commitments set for the next three years [1][2]. Group 1: Control Change and Financial Commitments - Yiming Pharmaceutical's controlling shareholder, Gao Fan, signed a share transfer agreement to sell 43,855,883 shares at a price of 15.1 yuan per share, totaling 662 million yuan, which represents 23% of the company's total shares [2]. - Following the transfer, the controlling shareholder will change from Gao Fan to Beijing Fuhai, with Yao Jinbo becoming the actual controller, reducing Gao Fan's voting rights from 25.59% to 2.59% [2]. - Gao Fan has made performance commitments, including a minimum net profit of 30 million yuan and revenue of at least 600 million yuan for the years 2025-2027 [3]. Group 2: Company Performance and Market Position - Yiming Pharmaceutical reported a revenue of approximately 652 million yuan in 2024, a decrease of 2.27% year-on-year, while achieving a net profit of 45.93 million yuan, a significant increase of 198.5% [6]. - The core product, Miglitol tablets, contributed 72.72% of the total revenue in 2024, amounting to 474 million yuan, and has shown consistent revenue growth over the past three years [6]. - In 2023, Yiming Pharmaceutical's revenue was 667 million yuan, reflecting a decline of 22.14%, attributed to changes in market conditions and underperformance of third-party cooperative products [7].